Key result
Low-dose aspirin initiated before 12 weeks' gestation in high-risk women did not significantly improve the pregnancy rate (RR 0.98) compared to placebo or no treatment.
Why the study?
The study was conducted to evaluate whether low-dose aspirin in the first trimester (≤12 weeks) can improve adverse pregnancy outcomes, pregnancy complications, and adverse reactions in pregnant women.
Does low-dose aspirin administered at <12 weeks' gestation improve pregnancy rate, live birth rate, and pregnancy complications in high-risk pregnant women?
Meta-Analysis (n=6,173)
Does low-dose aspirin administered at <12 weeks' gestation improve pregnancy rate, live birth rate, and pregnancy complications in high-risk pregnant women?
Relative Risk: 0.98 (95% CI 0.93–1.03)
p-value: p=0.50
Administration of low-dose aspirin at <12 weeks' gestation in high-risk women does not significantly improve pregnancy rates, live birth rates, or reduce pregnancy complications.
Purpose:The aim of the present study was to evaluate low-dose aspirin in the first trimester (≤12 weeks) whether or not can improve adverse pregnancy outcomes, such as pregnancy rate, live birth rate, pregnancy complications, and adverse reactions in pregnant women using a model‐based meta‐analysis.MethodsA systematic literature search of public databases was conducted. Entry criteria were randomized controlled trials evaluating the effect of aspirin administered at <12 weeks’ gestation compared to placebo or no-treatment. ResultsThe entry criteria were fulfilled by 22 randomized controlled trials on a combined total of 6173 participants. The main findings of this study were that for women with recurrent miscarriage, antiphospholipid antibodies, and IVF/ICSI treatment, the first trimester (<12 weeks) use of low dose aspirin for the pregnancy rate, fertility, pregnancy complications and aspirin adverse reactions had no significant effect. ConclusionsThis study demonstrated that the administration of low-dose aspirin at <12weeks’ gestation in high risk women does not change the pregnancy rate, the birth rate, the risk of pregnancy complications and aspirin adverse reactions.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2022) conducted a meta-analysis in High-risk pregnancy (recurrent miscarriage, antiphospholipid antibodies, IVF/ICSI) (n=6,173). Low-dose aspirin vs. Placebo or no-treatment was evaluated on Pregnancy rate (RR 0.98, 95% CI 0.93-1.03, p=0.50). Low-dose aspirin initiated before 12 weeks' gestation in high-risk women did not significantly improve the pregnancy rate (RR 0.98) compared to placebo or no treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: